Anti-SARS-CoV-2 Antibody Seroprevalence Surveys in India: An Insight into Current COVID-19 Pandemic Situation

• Main Authors: Sudarshan Ramaswamy, Arpit Arora, Aditya Athotra, Meera Dhuria, Arti Bahl, Anil Digambar Patil, Sudhir Kumar Jain, Sujeet Kumar Singh
• Format: Article
• Language: English
• Published: JCDR Research and Publications Private Limited 2021-07-01
• Series: Journal of Clinical and Diagnostic Research
• Subjects: : herd immunity; infection case ratio; seroepidemiologic studies; vaccination
• Online Access: https://jcdr.net/articles/PDF/15123/48633_CE[Ra1]_F[IK]_PF1(SY_SHU)_PFA(SY_KM)_PN(KM).pdf
• ISSN: 2249-782X; 0973-709X

Antibody test is used in seroprevalence surveys for Coronavirus Disease-2019 (COVID-19). Apart from estimating the proportion of population infected, they can help in drawing plenty of inferences about the extent, progress and course of the pandemic. They can potentially be helpful in planning and prioritising vaccine distribution by providing a broad overview into proportion of population immune to COVID-19 in a geographic area and also help in understanding the pockets of high or low seroprevalence. This review was conducted with an aim of compiling an updated and comprehensive information about the seroprevalence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody in various pockets of India in the year 2020, and thus to understand the current pandemic situation in the country. A total of 35 studies were identified through all resources and detailed review was carried out based on these studies. Additionally, indicators were devised to understand and compare the results. Results were further classified into states/Union Territories (UTs), districts, Sub-district regions. The study findings show that the anti SARSCoV-2 antibodies seroprevalence estimates vary across different regions (states/UTs, districts, sub district regions) of India and can increase or in some instances decrease over the course of time. The study concludes by asserting the need for repeated seroprevalence surveys as well as follow-up studies for current pandemic surveillance.